Table 1

Demographics, medications and disease activity for RA patients and controls
Clinical features Early RA Late RA Healthy controls
(n = 15) (n = 13) (n = 15)
Age, yrs (median, range) 57 (36 to 87) 69 (43 to 84) 51 (37 to 62)
Female: male 11:4 8:5 13:2
Duration of RA, months 54 (48 to 72) 240 (83 to 456)
Ethnicity: Caucasian (%) 87 85 87
Anti-CCP antibody + VE (%) 93 92
RF positive (%) 60 69
Medications – No. (%)
NSAIDs 4 (27) 3 (23)
MTX alone* 3 1
cDMARD combinations**
 MTX, SSZ, HCQ 0 2
 MTX, HCQ, LEF 1 0
 MTX, LEF 2 0
 MTX, LEF, HCQ 0 1
 MTX, LEF, SSZ 1 0
 MTX, SSZ 0 2
 MTX, HCQ 3 1
 MTX, IM gold, LEF 0 1
 HCQ, LEF 1 0
Prednisone 2.5 to 10 mg/d 4 (27) 2 (15)
bDMARDs*** 1 (7) 4 (31)
 ETC 1 1
 ADA 0 3
Disease activity (median, range)
Tender joint count (68) 8 (1 to 36) 17 (0 to 40)
Swollen joint count (66) 1 (0 to 6) 3 (0 to 8)
Pain VAS (mm) 14 (2 to 91) 20 (0 to 47)
Global VAS (mm) 2 (0 to 4) 2 (0 to 3)
HAQ score 0.75 (0 to 1.75) 0.88 (0 to 2.5)
PF SF - 36 65 (5 to 100) 65 (5 to 95)
CRP (mg/l) 2 (1 to 36) 4 (1 to 13) 1.2 (1 to 9)
DAS28CRP3v 3.1 (1.5 to 4.8) 3.6 (1.9 to 4.8)

ADA, adalimumab 40 mg fortnightly; anti-CCP, antibodies to cyclic citrullinated peptide; bDMARDs, biological disease modifying antirheumatic drugs; cDMARDs, conventional disease modifying anti-rheumatic drugs; CRP, C-reactive protein; DAS28CRP3v, disease activity score 28, 3 variable CRP; HAQ, health assessment questionnaire; HCQ, hydroxychloroquine 200 to 400 mg/day; IM gold, myocrisin 50 mg/month; LEF, leflunomide 10 to 20 mg/day; NSAIDs, nonsteroidal anti-inflammatory drugs; PF SF-36, physical function component of short form-36 score; RF, rheumatoid factor; VAS, visual analogue scale.

*MTX, methotrexate 10 to 25 mg/week; **SSZ, sulphasalazine 1 to 3 g/day; ***ETC, etanercept 50 mg/week.

McQueen et al.

McQueen et al. Arthritis Research & Therapy 2014 16:R33   doi:10.1186/ar4462

Open Data